These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 24470552)

  • 1. Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus.
    Antoszczyk S; Spyra M; Mautner VF; Kurtz A; Stemmer-Rachamimov AO; Martuza RL; Rabkin SD
    Neuro Oncol; 2014 Aug; 16(8):1057-66. PubMed ID: 24470552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
    Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Canron X; Bikfalvi A; Martuza RL; Kurtz A; Rabkin SD
    Clin Cancer Res; 2006 Nov; 12(22):6791-9. PubMed ID: 17121900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model.
    Mahller YY; Vaikunth SS; Currier MA; Miller SJ; Ripberger MC; Hsu YH; Mehrian-Shai R; Collins MH; Crombleholme TM; Ratner N; Cripe TP
    Mol Ther; 2007 Feb; 15(2):279-86. PubMed ID: 17235305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malignant peripheral nerve sheath tumors with high and low Ras-GTP are permissive for oncolytic herpes simplex virus mutants.
    Mahller YY; Rangwala F; Ratner N; Cripe TP
    Pediatr Blood Cancer; 2006 Jun; 46(7):745-54. PubMed ID: 16124003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models.
    Zhang W; Fulci G; Wakimoto H; Cheema TA; Buhrman JS; Jeyaretna DS; Stemmer Rachamimov AO; Rabkin SD; Martuza RL
    Neoplasia; 2013 Jun; 15(6):591-9. PubMed ID: 23730207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic measles virus as a novel therapy for malignant peripheral nerve sheath tumors.
    Deyle DR; Escobar DZ; Peng KW; Babovic-Vuksanovic D
    Gene; 2015 Jul; 565(1):140-5. PubMed ID: 25843626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of human thyroid carcinoma cells with the g47delta oncolytic herpes simplex virus.
    Wang JN; Xu LH; Zeng WG; Hu P; Rabkin SD; Liu RR
    Asian Pac J Cancer Prev; 2015; 16(3):1241-5. PubMed ID: 25735362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy.
    Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Martuza RL; Rabkin SD; Kurtz A
    Mol Ther; 2006 Dec; 14(6):789-97. PubMed ID: 17045531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus.
    Nigim F; Esaki S; Hood M; Lelic N; James MF; Ramesh V; Stemmer-Rachamimov A; Cahill DP; Brastianos PK; Rabkin SD; Martuza RL; Wakimoto H
    Neuro Oncol; 2016 Sep; 18(9):1278-87. PubMed ID: 26951380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models.
    Saha D; Wakimoto H; Peters CW; Antoszczyk SJ; Rabkin SD; Martuza RL
    Clin Cancer Res; 2018 Jul; 24(14):3409-3422. PubMed ID: 29599413
    [No Abstract]   [Full Text] [Related]  

  • 11. Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy.
    Ghonime MG; Cassady KA
    Cancer Immunol Res; 2018 Dec; 6(12):1499-1510. PubMed ID: 30352799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.
    Kanai R; Rabkin SD; Yip S; Sgubin D; Zaupa CM; Hirose Y; Louis DN; Wakimoto H; Martuza RL
    J Natl Cancer Inst; 2012 Jan; 104(1):42-55. PubMed ID: 22173583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-tumor effect of oncolytic herpes simplex virus G47delta on human nasopharyngeal carcinoma.
    Wang JN; Hu P; Zeng MS; Liu RB
    Chin J Cancer; 2011 Dec; 30(12):831-41. PubMed ID: 22059912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect.
    Kolodkin-Gal D; Edden Y; Hartshtark Z; Ilan L; Khalaileh A; Pikarsky AJ; Pikarsky E; Rabkin SD; Panet A; Zamir G
    Gene Ther; 2009 Jul; 16(7):905-15. PubMed ID: 19440231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncolytic herpes simplex virus treatment of metastatic breast cancer.
    Wang J; Hu P; Zeng M; Rabkin SD; Liu R
    Int J Oncol; 2012 Mar; 40(3):757-63. PubMed ID: 22108767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
    Todo T
    Front Biosci; 2008 Jan; 13():2060-4. PubMed ID: 17981691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular engineering and validation of an oncolytic herpes simplex virus type 1 transcriptionally targeted to midkine-positive tumors.
    Maldonado AR; Klanke C; Jegga AG; Aronow BJ; Mahller YY; Cripe TP; Crombleholme TM
    J Gene Med; 2010 Jul; 12(7):613-23. PubMed ID: 20603890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival.
    Bommareddy PK; Wakimoto H; Martuza RL; Kaufman HL; Rabkin SD; Saha D
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38599661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts.
    Cheema TA; Kanai R; Kim GW; Wakimoto H; Passer B; Rabkin SD; Martuza RL
    Clin Cancer Res; 2011 Dec; 17(23):7383-93. PubMed ID: 21976549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice.
    Thomas ED; Meza-Perez S; Bevis KS; Randall TD; Gillespie GY; Langford C; Alvarez RD
    J Ovarian Res; 2016 Oct; 9(1):70. PubMed ID: 27784340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.